Account wins
MedThink Communications has been retained by Salix Pharmaceuticals to launch and promote its newest product under development, an orally disintegrating form of metoclopramide.
<< Return to
Account wins
Your Email Address:
Recipient(s) Email Address:
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
Include a message (optional):
The e-mail address(es) that you supply to use this service will only be used to send the requested article.